Formulation And Evaluation Of Sustained Release Matrix Tablet Of Diltiazem Hcl

Abstract

Controlled Release And Sustained Release Drug Delivery Has Become The Standards In The Modern Pharmaceutical Design And Intensive Research For Achieving Better Drug Product Effectiveness, Reliability And Safety. Oral Sustained Release Drug Delivery (OSRDD) Medication Will Continue To Account For The Largest Share (up To 80%) Of Drug Delivery Systems. The Matrix Tablet Preparation Appears To Be Most Attractive Approach For The Process Development And Scale-up Point Of View. A Calcium Channel Blocker, Diltiazem Hydrochloride Has Found Its Applicability In Cardiovascular Diseases Advised To Take The Long Term Treatment Of Cardiovascular Medicaments Like Anti-anginals, Anti-hypertensives, Etc. The Calcium Channel Blockers Are Utilized As The Potential Agents For The Treatment Of These Diseases. They Are Considered As A Slow Calcium Channel Blockers. The Direct Compression Method Was Adopted For The Preparation Of Sustained Release Matrix Tablets With The 10mm Punches And Targeted Weight Of 450mg. The % Drug Release Studies For Combined Hypromellose And Xanthan Gum Matrices Confirmed The Batch H2X2 (at The End Of 12 Hours) As Per USP Criteria Test 2, Which Give The 93.78% Drug Release. Hence, This Formulation Was Optimized And Subjected To Release Kinetic Study And Accelerated Stability Studies.

Keywords